報價延遲最少15分鐘:2026/05/06 12:41 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.8 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.94/--
|
|
企業價值
851.89M
|
| 資產負債 |
|
每股賬面淨值
-1.75
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects. |
